Gold Prices Rebound in Europe as Geopolitical Tensions and Fed Outlook Support Bullion 
Asia Manufacturing PMI Rebounds as Exports and Tech Demand Drive Growth into 2026 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
South Korea Factory Activity Returns to Growth in December on Export Rebound 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Renault Group Global Sales Rise 3.2% in 2025 on Strong International and EV Demand 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
Asian Currencies Trade Flat as Dollar Weakens in Thin New Year Trading 
China Imposes 55% Tariff on Beef Imports Above Quota to Protect Domestic Industry 
Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Trump Delays Tariff Increases on Furniture and Cabinets for One More Year 
U.S. Stocks Slip as Gold Rebounds Ahead of Year-End, Markets Eye 2026 Outlook 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Celltrion, a South Korean pharmaceutical company, revealed on Thursday, Aug. 12, that it has received emergency approval from the government of Brazil for its COVID-19 antibody treatment.
According to The Korea Herald, Celltrion shared that the Health Regulatory Agency of the said country granted emergency use authorization (EUA) for its Regkirona or CT-P59, which is a COVID-19 treatment. It was said that the agency made the decision based on the results of the drug’s clinical tests for all three phases.
Celltrion added that the Brazilian health agency also looked into their preclinical studies that show the efficacy of the treatment against COVID-19 variants. Once it is made available in Brazil, Regkirona will be utilized for the treatment of adult patients who are at higher risk from COVID-19 and experiencing both mild and severe symptoms.
Korea Biomedical Review reported that adults aged 65 or older with mild and moderate symptoms would also be treated with Celltrion’s antibody drug. With the high number of daily coronavirus cases in Brazil today, Celltrion said it will deliver Rekirona to the country as fast as it could to help treat the patients.
In the COVID-19 world statistics on Worldometer, Brazil has more than 20 million cases of coronavirus infection and more than 560,000 deaths. With the spread of the more contagious Delta variant, the country is recording daily cases of around 10,000 to 30,000.
“Based on the safety and efficacy proven through large-scale global clinical data of Regkirona, the company has obtained emergency use approval from the Brazilian health authorities,” a Celltrion official stated. “We will do our best to contribute to preventing the spread of Covid-19 by supplying Regkirona early to Brazil, where the number of confirmed cases has recently rapidly increased to 30,000 a day due to the spread of the Delta variant.”
Celltrion declared that its Rekirona antibody treatment drug could reduce the risk of the coronavirus infection from progressing to a severe stage. The pharmaceutical firm further said that it could lessen the recovery time as well. Meanwhile, with the Brazilian EUA, Celltrion is planning to submit an application for similar authorization in the U.S.
